'Pay-for-delay' settlements between drug patent-holders and generics manufacturers to delay the launch of cheaper generic medicine are increasingly being scrutinised by antitrust regulators
The 50-share NSE Nifty was trading lower by 24 points.
Forbes said Prime Minister Narendra Modi's "economic experiments" barely affected India's billionaires while none gained more than oil-and-gas tycoon Mukesh Ambani, who cemented his decade-long hold on the top slot by adding a staggering USD 15.3 billion (67 per cent) to his last year's wealth to become one of Asia's top five richest.
Another year of strong performance by these export-oriented sectors likely as US economy revives and rupee is expected to be under pressure.
The BSE Midcap and Smallcap indices underperformed the largecaps and ended over 1% lower.
These investors are not only betting on little-known stocks, but also sectors that the market participants are not paying much heed to. Some of these stocks can be potential multi-baggers, while others may not live up to the expectations of these stock-pickers, says Jash Kriplani.
.jpg)
In a letter to health minister Harsh Vardhan, the Indian Pharmaceutical Alliance, an industry body representing leading pharma companies, including Sun Pharma, Lupin, Dr Reddy's Labs, Cadila Health and Glenmark, stressed the need for an out-of-court settlement with health activists fighting for the rights of clinical trial participants.
The BSE Midcap ended up 0.5% while the Smallcap index ended nearly 1% higher
Earning woes drag markets lower; TCS, HUL lead fall.
Ajit Mishra, vice president, Research, Religare Broking, answers readers' queries on stocks they own or want to buy.
Combined net profit estimated to grow 14.6% year-on-year, against a 5.7% decline in the Dec 2015 quarter
The Sensex closed down 308 points at 24,894 and the Nifty has lost 96 points at 7,559.
This is to take head on big American pharmaceutical giants, which in the recent past had launched a strong anti-India campaign against efforts of such companies to provide affordable health care not only to people in India, but also in the third world countries.
The Delhi High Court on Friday stayed the ban on some fixed dose combination (FDC) drugs of Glaxo SmithKline, Wockhardt and Laboratories Griffon but said action against their sale could be taken in the absence of valid sale and marketing licence.
Additional levy to eat into Rs 6,000-crore income of top promoters
The recovery was led by pharma majors led by Dr Reddy's Labs.
Indian loses chance to be research hub as domestic drug companies move R&D overseas.
And when an inspector asked about the contents of unlabelled vials in the laboratory glassware washing area, a plant worker dumped them down a sink and said the contents could not be determined, according to a July 18 letter from the US Food and Drug Administration to Wockhardt, which makes sterile injectable drugs and various forms of insulin.
Once tipped to emerge as the biggest exporter, the pharmaceutical industry is yet to acquire the scale of those in software services, says Krishna Kant.
50-odd biz leaders are part of Modi's entourage for the 3-nation tour
Expectations of strong results, consistent performance and investors preference for stocks in the defensive space help the sector outshine broader markets.
Nifty is likely to remain under selling pressure unless and until it breach the 7,700-7,720 levels on closing basis.
This analysis is based on the quarterly earnings for 724 companies.
Market breadth is positive with 942 advances and 196 declines.
The local markets are expected to react to global triggers until the government announces the Union Budget.
Financials were the top losers while oil shares also declined amid weak crude oil prices.
Besides opposing the suspension of three medicines, the sector has also questioned the process adopted by the government.
Investors must be cautious and follow a prudent diversification strategy to mitigate against any risks in case of any unforeseen events.
Nifty50 surged 87 points to end at 8,157, highest closing levels since Oct 29, 2015.
Media tycoon Kalanithi Maran and his wife Kavery Kalanithi have retained the top two slots among the highly paid executives in the country.
The Indian Pharmaceutical Alliance has approached regulator for a dialogue to understand the concern raised by it
Developed markets have performed better than emerging market firms in the top 10 TSR-based rankings, says a BCG report.
Analysts now expect India Inc to report a decline in both top line and bottom line for the September quarter.
The higher rate cut by RBI is positive for rate-sensitive sectors in the medium to long term.
Ten months after new Sebi norms set in, some senior directors still hold more board seats than allowed.
The S&P BSE Sensex has rallied about 28 per cent in 2014, after formation of a stable government at the Centre.
'How did Hermoine fall for Weasley?' 20 years after Harry Potter made his debut, Vanita Kohli-Khandekar has some questions for its author
Analysts mostly prefer domestic plays beside select films with foreign exposure.
Sharp fall in capital goods production and manufacturing activity also dented sentiments.
Market breadth continued to remain strong, with 1899 gainers and 674 losers on the BSEs.
